lenvanix-10/*54745756836*/
lenvanix-10
Categories: Anti-Diabetic, BEST SELLER, Diabetic, Endometrial Cancer, Liver Cancer, Lymphoma, ONCOLOGY PRODUCTS, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Primary Biliary Cirrhosis, Renal Cell Carcinoma, Rheumatoid Arthritis
Tags: ACLOPAIN, Afanix Tablet, Axitinib, BARICINIX 4 MG, Baricitinib, Beacon Pharmaceuticals Ltd., CABOZANIB, lenvanix, lenvanix-10, Medicine in Bangladesh, Oncology Medicine Supplier, Oncology Medicine Supplier in Bangladesh
Reviews (0)
Be the first to review “lenvanix-10” Cancel reply
Shipping & Delivery
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing/*54745756836*/
Related products
AXINIX 5 MG
DESCRIPTION Axinix (Axitinib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma after failure of one
ALECNIB 150 MG
DESCRIPTION Alecnib, Alectinib Alecnib is an anti-cancer targeted chemotherapy drug used for the treatment of cancer. Alecnib is a tyrosine
BARICINIX 4 MG
Product Description: Baricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded
AFANIX 40 MG
Afatinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose
CRIZOCENT 250 MG
Presentation Crizocent 250: Each capsule contains Crizotinib INN 250 mg Description Crizotinib is an inhibitor of receptor tyrosine kinases including
ELOPAG 25 MG
Elopag Tablet Eltrombopag Olamine 25 mg Everest Pharmaceuticals Ltd. Indications Eltrombopag Olamine is indicated in Chronic Immune (Idiopathic) Thrombocytopenia, Chronic Hepatitis
DACLAXEN 60 MG
Indications Daclatasvir is indicated in combination with Sofosbuvir for the treatment of chronic hepatitis C virus (HCV) infection in adults.
HERNIX 40 MG
Hernix Tablet Neratinib 40 mg Beacon Pharmaceuticals Ltd. Indications Neratinib is a kinase inhibitor indicated for the extended adjuvant treatment of
Reviews
There are no reviews yet.